Therapeutic Applications

Cyclic Peptide
Applications in
Oncology

Design constrained peptide ligands for tumor target engagement, selective delivery and radioligand development—from target assessment to an experimentally testable candidate series.

Discuss an Oncology Target →
Conceptual bicyclic peptide ligand engaging a tumor cell surface receptor with a linked payload
Application Overview

One Molecular Format, Several Oncology Strategies

Cyclic peptides can act as target-binding molecules in their own right or serve as compact recognition elements within a larger therapeutic assembly. In oncology, these roles lead to different project decisions. A direct inhibitor must engage a disease-relevant interface and change its function. A drug conjugate must bind the chosen tumor antigen, deliver a payload and release it in the intended context. A radioligand must combine target localization with a chelator, isotope and exposure pattern suited to imaging or therapy.

We begin with the desired mechanism, the target's expression in tumor and normal tissues, and the route by which a molecule can reach it. Those inputs guide ring topology, ligand discovery, linker design and the order of experiments. A project targeting a cell-surface antigen may prioritize accessible epitopes, internalization and tumor retention; an intracellular PPI project instead needs evidence of cell entry and engagement in the relevant compartment.

This page provides an application map across the three routes. Each route connects to detailed cyclic peptide services for discovery, structure and property optimization, synthesis planning and validation. The output of the first stage is a target-specific design brief and a focused experimental plan.

Three Application Paths

Match the Peptide to the Mechanism

01 / Direct Engagement

Inhibit a Tumor-Relevant Interaction

A cyclic peptide can be developed to bind an extracellular receptor or disrupt a protein interface. Target selection begins with structural and functional evidence. The campaign then compares binding geometry, activity in relevant cells, selectivity and exposure. For an intracellular target, permeability and subcellular engagement become central selection criteria.

Explore PPI inhibitor design →

02 / Targeted Delivery

Guide a Payload to a Tumor Antigen

A targeting peptide can be joined to a cleavable linker and a cytotoxic payload. Ligand affinity is only one component: target density, internalization, plasma stability, release kinetics and off-tumor exposure determine whether the assembly performs its intended role. Bicyclic peptide conjugates targeting Nectin‑4 and EphA2 illustrate this design space.1,2

Explore conjugate design →

03 / Radioligands

Localize an Imaging or Therapeutic Isotope

A peptide ligand can carry a chelator for a diagnostic or therapeutic radionuclide. Development considers binding, tumor uptake, normal-organ distribution, residence time and isotope choice as one system. The approved somatostatin-receptor radiopharmaceutical lutetium Lu 177 dotatate demonstrates the clinical relevance of peptide-guided radionuclide delivery.3

Explore radioligand questions →

Target Selection

Choose a Target in Its Tumor Context

Tumor and Normal-Tissue Expression

Review target abundance across patient tumors, tumor subtypes and healthy tissues. A strong signal in a tumor sample is interpreted alongside cellular localization and normal-organ expression. Candidate antigens can then be grouped by the expected therapeutic window and by the assays available to evaluate it.

Epitope Accessibility and Internalization

Map exposed receptor domains and possible ligand-binding pockets. Direct antagonists require an interface linked to function. Payload delivery projects additionally ask whether the bound complex is internalized and processed in a way that releases an active drug. Imaging ligands may prioritize accessible surface binding and target retention.

Heterogeneity and Patient Selection

Consider the fraction of target-positive cells, variation within lesions and changes across disease sites. A patient-selection assay can be developed around protein expression or an imaging signal. Early design can include targets and controls that show whether a candidate's activity follows antigen abundance.

Nectin‑4 and EphA2 are useful public examples of tumor-antigen programs. Bicycle Therapeutics reports Nectin‑4-targeting zelenectide pevedotin and EphA2-targeting nuzefatide pevedotin in its pipeline; their ligand, linker and MMAE payload components offer concrete reference points for how a tumor-targeted peptide conjugate is assembled.1

Conjugate Co-Design

Optimize the Whole Peptide–Linker–Payload Assembly

Changing a cyclic peptide ligand can alter target affinity, selectivity and the location of a viable conjugation handle. Changing the linker can alter stability during circulation and release after target uptake. Changing the payload can alter potency, membrane permeability and the effects on neighboring cells. These components should therefore be compared as a connected series with matched controls.

Our computational and experimental plan begins with a target-binding ligand and defines the intended delivery mechanism. We inspect conjugation sites that preserve the binding face, compare linker chemistry and length, then evaluate the resulting assemblies for physicochemical properties and synthetic feasibility. A staged test set includes the free ligand, conjugate, suitable nonbinding control and payload-related controls.

Binding and internalization assays establish whether the assembly reaches the intended cell population. Cytotoxicity across target-high and target-low models then tests the relationship between antigen expression and response. Plasma stability and metabolite studies help identify premature release. In vivo distribution and efficacy studies can be scoped around the questions remaining after those measurements.

ComponentDesign decisionKey readout
Cyclic peptide ligandRing topology, epitope, affinity and selectivityBinding across target and counter-target panels
Attachment sitePosition that preserves target recognitionFree ligand versus conjugated ligand activity
LinkerCirculatory stability and intracellular releaseStability, cleavage and metabolite profile
PayloadMechanism, potency and release-product propertiesTarget-dependent cell response
Complete conjugateExposure and tissue distributionInternalization, PK and tumor-to-normal-tissue signal
Radioligand Applications

Design for Tumor Uptake and Normal-Organ Distribution

Radioligand projects use a receptor-binding peptide as a targeting unit. The ligand is connected to a chelator that holds a selected radionuclide. An imaging program seeks a signal that distinguishes target-positive lesions from background; a therapeutic program must also consider absorbed dose in tumor and normal organs. Target expression, affinity, dissociation, internalization and clearance shape that balance.

Lutetium Lu 177 dotatate couples the somatostatin analog octreotate to DOTA and delivers radiation to somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors. It provides a clinically established example of a peptide-based targeting concept.3 In newer research programs, a bicyclic peptide may provide a compact ligand with a distinct epitope or clearance pattern. The chelator attachment site and the chemical identity of the labeled product remain part of the design, not an afterthought.

Conceptual cyclic peptide linked to a chelator-like motif near a tumor cell receptor

Ligand, Linker, Chelator and Isotope

These modules are assessed together. We compare whether a chelator changes target engagement, whether the labeled construct retains integrity, and how the selected isotope's physical properties fit the biological residence time.

An initial study can pair receptor binding and cellular uptake with stability and small-animal biodistribution. The next design round then focuses on tumor retention, kidney and other normal-organ exposure, and practical labeling conditions.

Public Development Examples

Examples That Clarify Different Design Decisions

EphA2-Targeting Bicyclic Peptide Conjugate

Nuzefatide pevedotin (formerly BT5528) combines an EphA2-targeting bicyclic peptide, a cleavable valine–citrulline linker and MMAE. The company reported an ongoing phase 2 study in recurrent pancreatic ductal adenocarcinoma as of October 2026.1,2

The case illustrates target-expression assessment, ligand–linker compatibility and the need to connect target binding with payload delivery. A new EphA2-related program would define its own epitope, ligand chemistry and tumor model at the outset.

Nectin‑4-Targeting Bicyclic Peptide Conjugate

Zelenectide pevedotin (formerly BT8009) combines a Nectin‑4-targeting bicyclic peptide with a cleavable linker and MMAE. Its randomized Duravelo‑2 trial concerns metastatic urothelial cancer; the company reported in 2026 that it had deprioritized internal development of this program.1,2,4

The example is especially useful for discussing antigen distribution, biomarker strategy and the interpretation of clinical development decisions alongside molecular design.

These public programs show how modularity creates multiple optimization levers. They also show why an oncology application page should route visitors by mechanism and experiment, rather than treat all cyclic peptide candidates as one product type.

Integrated Workflow

From Tumor Biology to Candidate Evidence

1 · Target contextAssess expression, accessibility, tumor heterogeneity and the intended mechanism.
2 · Ligand discoveryDesign or screen cyclic peptide scaffolds and nominate diverse binding candidates.
3 · Modality selectionChoose direct inhibitor, drug conjugate or radioligand from the biological objective.
4 · Assembly designOptimize ring geometry, conjugation site, linker and payload or chelator.
5 · ValidationConnect binding to cell activity, internalization, stability and biodistribution.

At each stage, the comparison set is built around one decision. A target-led program may begin with receptor-domain constructs and expression profiling. A ligand-led program may begin with an epitope and selectivity panel. A conjugate-led program may begin with matched attachment-site variants, while a radioligand program may start by comparing labeled and unlabeled ligand binding. The workflow produces a candidate series and the data needed to select its next experiment.

Experimental Decision Points

Measure the Property That Limits Progression

Binding strength alone does not establish tumor delivery or functional effect. We pair target-level data with cell and organism-level measurements chosen for the modality. A direct antagonist is assessed for pathway modulation. A conjugate is assessed for internalization and released-payload activity. A radioligand is assessed for labeled-product stability, lesion uptake and normal-organ distribution.

Comparisons use matched parent ligands and controls so that a change in ring geometry, conjugation site or linker can be interpreted. This approach helps separate a ligand problem from a release, labeling or exposure problem.

ProgramEarly evidenceNext selection question
Direct inhibitorAffinity, selectivity, pathway response, cell engagementDoes target engagement produce the intended biological effect?
Peptide drug conjugateLigand binding, internalization, linker stability, target-dependent cytotoxicityIs delivery selective and is payload release in the intended compartment?
Imaging ligandLabeling, radiochemical purity, receptor binding, tissue uptakeIs lesion signal distinct from background and normal-organ uptake?
Therapeutic radioligandTarget retention, biodistribution, dosimetry-related inputsDoes tumor exposure support the intended therapeutic window?
Project Deliverables

Outputs for Oncology Discovery and Optimization

Target and Tissue Context Brief

Target biology, expression and accessibility summary, proposed mechanism and assay strategy.

Prioritized Ligand Series

Defined cyclic peptide structures, ring constraints, interface hypotheses and synthesis order.

Modality Design Matrix

Direct-inhibitor, conjugate or radioligand options mapped to project-specific success criteria.

Attachment and Linker Review

Selected conjugation positions, linker alternatives, chemistry and structural verification plan.

Validation Package

Binding, cell-response, internalization, stability and distribution experiments with matched controls.

Candidate Decision Report

Integrated evidence, remaining gaps and a focused proposal for the next design round.

Start a Program

Share a Tumor Target or a Peptide Lead

Tell us the target, cancer setting, intended mechanism, available structural or expression data, and whether the program concerns direct engagement, payload delivery or radioligand development. We can define a focused first design and validation phase.

Start an Inquiry →

References

  1. Bicycle Therapeutics. Pipeline and program descriptions.
  2. Bicycle Therapeutics. Third quarter 2026 business progress. October 29, 2026.
  3. US Food and Drug Administration. Lutathera multidisciplinary review; lutetium Lu 177 dotatate for SSTR-positive GEP-NETs.
  4. ClinicalTrials.gov. NCT06225596: Duravelo‑2 study of zelenectide pevedotin.

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.